Exelixis Inc.

20.94-1.28-5.76%Vol 2.29M1Y Perf 23.31%
Jun 28th, 2022 16:00 DELAYED
BID20.25 ASK20.97
Open22.27 Previous Close22.22
Pre-Market- After-Market20.96
 - -  0.02 0.10%
Target Price
28.09 
Analyst Rating
Strong Buy 1.50
Potential %
34.15 
Finscreener Ranking
★★★★★     58.72
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★+     57.97
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     75.66
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
68.86 
Earnings Rating
Strong Buy
Market Cap6.72B 
Earnings Date
4th Aug 2022
Alpha0.00 Standard Deviation0.14
Beta0.76 

Today's Price Range

20.5622.28

52W Range

15.5023.40

5 Year PE Ratio Range

-49.0073.60

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
14.83%
1 Month
20.76%
3 Months
2.16%
6 Months
17.94%
1 Year
23.31%
3 Years
3.98%
5 Years
-7.49%
10 Years
306.96%

TickerPriceChg.Chg.%
EXEL20.94-1.2800-5.76
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Earnings HistoryEstimateReportedSurprise %
Q01 20220.140.2150.00
Q04 20210.070.29314.29
Q03 20210.190.12-36.84
Q02 20210.050.30500.00
Q01 20210.040.00-100.00
Q04 20200.030.09200.00
Q03 2020-0.05-0.10-100.00
Q02 20200.120.2175.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR0.210.00-
9/2022 QR0.22-4.35Negative
12/2022 FY0.897.23Positive
12/2023 FY1.196.25Positive
Next Report Date4th Aug 2022
Estimated EPS Next Report0.21
Estimates Count6
EPS Growth Next 5 Years %37.30
Volume Overview
Volume2.29M
Shares Outstanding320.74K
Shares Float283.57M
Trades Count27.33K
Dollar Volume48.36M
Avg. Volume2.57M
Avg. Weekly Volume2.62M
Avg. Monthly Volume2.56M
Avg. Quarterly Volume2.54M

Exelixis Inc. (NASDAQ: EXEL) stock closed at 22.22 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 1.82M shares and market capitalization of 6.72B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 773 people. Exelixis Inc. CEO is Michael M. Morrissey.

The one-year performance of Exelixis Inc. stock is 23.31%, while year-to-date (YTD) performance is 21.55%. EXEL stock has a five-year performance of -7.49%. Its 52-week range is between 15.5 and 23.4, which gives EXEL stock a 52-week price range ratio of 68.86%

Exelixis Inc. currently has a PE ratio of 23.90, a price-to-book (PB) ratio of 3.11, a price-to-sale (PS) ratio of 4.69, a price to cashflow ratio of 14.10, a PEG ratio of 2.32, a ROA of 12.62%, a ROC of 13.59% and a ROE of 14.54%. The company’s profit margin is 19.51%, its EBITDA margin is 25.60%, and its revenue ttm is $1.52 Billion , which makes it $4.74 revenue per share.

Of the last four earnings reports from Exelixis Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.21 for the next earnings report. Exelixis Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Exelixis Inc. is Strong Buy (1.5), with a target price of $28.09, which is +34.15% compared to the current price. The earnings rating for Exelixis Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Exelixis Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Exelixis Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 6.35, ATR14 : 0.79, CCI20 : 216.28, Chaikin Money Flow : 0.35, MACD : 0.40, Money Flow Index : 74.57, ROC : 15.61, RSI : 69.79, STOCH (14,3) : 95.48, STOCH RSI : 1.00, UO : 73.44, Williams %R : -4.52), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Exelixis Inc. in the last 12-months were: Alan M. Garber (Option Excercise at a value of $125 200), Alan M. Garber (Sold 21 301 shares of value $447 321 ), Carl B. Feldbaum (Option Excercise at a value of $125 200), Carl B. Feldbaum (Sold 40 000 shares of value $742 200 ), Charles Cohen (Option Excercise at a value of $252 000), Christopher J. Senner (Option Excercise at a value of $329 400), Gisela M. Schwab (Option Excercise at a value of $168 000), Jack L. Wyszomierski (Option Excercise at a value of $125 200), Jack L. Wyszomierski (Sold 6 696 shares of value $154 008 ), Jeffrey J. Hessekiel (Sold 82 234 shares of value $1 737 455 ), Patrick J. Haley (Option Excercise at a value of $124 200), Patrick J. Haley (Sold 70 050 shares of value $1 406 945 ), Peter Lamb (Option Excercise at a value of $399 475), Peter Lamb (Sold 102 500 shares of value $1 873 475 ), Stelios Papadopoulos (Sold 84 515 shares of value $1 653 113 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (66.67 %)
7 (63.64 %)
8 (66.67 %)
Moderate Buy
2 (16.67 %)
2 (18.18 %)
2 (16.67 %)
Hold
2 (16.67 %)
2 (18.18 %)
2 (16.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.55
Strong Buy
1.50

Exelixis Inc.

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma.

CEO: Michael M. Morrissey

Telephone: +1 650 837-7000

Address: 1851 Harbor Bay Parkway, Alameda 94502, CA, US

Number of employees: 773

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

53%47%

Bearish Bullish

61%39%

TipRanks News for EXEL

Mon, 23 May 2022 12:38 GMT Exelixis (EXEL) Gets a Buy Rating from Jefferies

- TipRanks. All rights reserved.

Fri, 13 May 2022 01:45 GMT Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (ARWR), Exelixis (EXEL) and Ontrak (OTRK)

- TipRanks. All rights reserved.

Wed, 19 Jan 2022 11:22 GMT Exelixis (EXEL) Gets a Buy Rating from H.C. Wainwright

- TipRanks. All rights reserved.

Wed, 05 Jan 2022 16:26 GMT Exelixis (EXEL) Receives a Buy from H.C. Wainwright

- TipRanks. All rights reserved.

News

Stocktwits